Peter - I agree with you except for one area. Big Pharma is needed to market our pipe line when that time comes. Therefore we will be partnering with people all the time.
I think the Roche deal is a model for what we will see in the future. Why not let someone with deep pockets take the risk out of the cost of trials? We could take a smaller percentage of sales if we don't have to spend 400 million up front. If you are doing that with multiple drugs at any given time the excitement level would be incredible. Giving up the right to market a drug does not mean giving up the ability to profit.
Let those that sell sell. We develop so let's develop. Let those with all the big bucks put up the money. Each does what they specialize in with virtually no risk To INO or it's cash on hand.
Another partnership to cover another trial(different drug) will push the stock up. Success of any kind could trigger payments from Roche which would strengthen the balance sheet again pushing the stock up. As this cycle continues eventually a drug comes to market creating on going revenue. As our delivery system is used by others to increase the effectiveness of their drugs another revenue stream adds to the balance sheet.
Rinse and repeat. The problem with going it alone is you will still most likely partner with others to market.
News 
Market Data 
Discover 
AI
